287 related articles for article (PubMed ID: 19414815)
1. Proteasome regulation of ULBP1 transcription.
Butler JE; Moore MB; Presnell SR; Chan HW; Chalupny NJ; Lutz CT
J Immunol; 2009 May; 182(10):6600-9. PubMed ID: 19414815
[TBL] [Abstract][Full Text] [Related]
2. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.
Kamimura H; Yamagiwa S; Tsuchiya A; Takamura M; Matsuda Y; Ohkoshi S; Inoue M; Wakai T; Shirai Y; Nomoto M; Aoyagi Y
J Hepatol; 2012 Feb; 56(2):381-8. PubMed ID: 21756848
[TBL] [Abstract][Full Text] [Related]
3. Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility.
Luis Espinoza J; Takami A; Trung LQ; Nakao S
Cancer Sci; 2013 Jun; 104(6):657-62. PubMed ID: 23445485
[TBL] [Abstract][Full Text] [Related]
4. MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells.
Luo D; Dong XW; Yan B; Liu M; Xue TH; Liu H; You JH; Li F; Wang ZL; Chen ZN
Mol Med Rep; 2019 Jan; 19(1):213-220. PubMed ID: 30483783
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response.
Ward J; Davis Z; DeHart J; Zimmerman E; Bosque A; Brunetta E; Mavilio D; Planelles V; Barker E
PLoS Pathog; 2009 Oct; 5(10):e1000613. PubMed ID: 19798433
[TBL] [Abstract][Full Text] [Related]
6. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
[TBL] [Abstract][Full Text] [Related]
7. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
8. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis.
Cerboni C; Zingoni A; Cippitelli M; Piccoli M; Frati L; Santoni A
Blood; 2007 Jul; 110(2):606-15. PubMed ID: 17405908
[TBL] [Abstract][Full Text] [Related]
9. Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands.
Müller S; Zocher G; Steinle A; Stehle T
PLoS Pathog; 2010 Jan; 6(1):e1000723. PubMed ID: 20090832
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing.
Richard J; Sindhu S; Pham TN; Belzile JP; Cohen EA
Blood; 2010 Feb; 115(7):1354-63. PubMed ID: 20008788
[TBL] [Abstract][Full Text] [Related]
11. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.
Soriani A; Zingoni A; Cerboni C; Iannitto ML; Ricciardi MR; Di Gialleonardo V; Cippitelli M; Fionda C; Petrucci MT; Guarini A; Foà R; Santoni A
Blood; 2009 Apr; 113(15):3503-11. PubMed ID: 19098271
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor.
López-Soto A; Quiñones-Lombraña A; López-Arbesú R; López-Larrea C; González S
J Biol Chem; 2006 Oct; 281(41):30419-30. PubMed ID: 16901903
[TBL] [Abstract][Full Text] [Related]
13. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
14. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.
Okita R; Yukawa T; Nojima Y; Maeda A; Saisho S; Shimizu K; Nakata M
Cancer Immunol Immunother; 2016 May; 65(5):499-509. PubMed ID: 26940474
[TBL] [Abstract][Full Text] [Related]
15. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
17. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
[TBL] [Abstract][Full Text] [Related]
18. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
19. A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells.
Gowen BG; Chim B; Marceau CD; Greene TT; Burr P; Gonzalez JR; Hesser CR; Dietzen PA; Russell T; Iannello A; Coscoy L; Sentman CL; Carette JE; Muljo SA; Raulet DH
Elife; 2015 Nov; 4():. PubMed ID: 26565589
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Natural Killer Group 2D Receptor Expression and That of Its Ligand in Ovarian Carcinomas: A Retrospective Study.
Lee GH; An HJ; Kim TH; Kim G; Park KS; Park H; Lee TH; Kwon AY
Yonsei Med J; 2021 Apr; 62(4):288-297. PubMed ID: 33779082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]